Repligen

BalançosRepligen

RGEN

A Repligen, com sede em Waltham, Massachusetts, é uma empresa global de ciências biológicas que desenvolve e vende equipamentos e suprimentos para bioprocessamento, incluindo anticorpos monoclonais, proteínas recombinantes, vacinas e terapias celulares e genéticas. Seus clientes incluem empresas biofarmacêuticas, CDMOs e outras empresas de ciências biológicas. Ela vende quatro categorias principais de produtos: filtração (incluindo gerenciamento de fluidos), 58% da receita de 2024, e cromatografia, proteínas e análise de processo, 19%, 12% e 9%, respectivamente. Clientes na América do Norte, Europa e Ásia-Pacífico contribuíram com 44%, 37% e 19% da receita.

Tabela de balanços completa e atualizada com os principais indicadores financeiros: Lucro Líquido, Receita, EBTIDA, Margem, ROE, Dividendos

Ano
12/2016
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2017
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2022
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2023
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2024
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2025
738
134
01
7%
0.86
2,106
2%
-182
-
85
-26
-15
59
-9
0
-
-